Added to YB: 2026-02-05
Pitch date: 2026-02-03
NVO [neutral]
Novo Nordisk A/S
-8.65%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 288.41
Price Target
N/A
Dividend
4.56%
EV/EBITDA
7.01
P/E
9.79
EV/Sales
3.73
Sector
Pharmaceuticals
Category
value
Show full summary:
Recontextualizing Novo Nordisk in the current obesity race
NVO (update): New CEO cutting 9K jobs, pill launched at $199-349/mo vs Lilly's $699, CVS Caremark chose Wegovy over Zepbound for May 2025, 4-6mo head start as Lilly's pill delayed to Q2. Despite Tirzepatide showing better weight loss, real-world dosing narrows gap. Strong MACE results opening cardio market.
Read full article (5 min)